N4 Pharma股份上升了7.3%,尽管每季度损失一次,贸易额强劲,口服RNA治疗平台也取得进展,对此起到了推动作用。 N4 Pharma shares rose 7.3% despite a quarterly loss, fueled by strong trading volume and progress on its oral RNA therapy platform.

N4 Pharma股份在交易量猛增50%至347万股的驱动下, 于星期四上涨7.3%至0.64GBX, N4 Pharma shares rose 7.3% to GBX 0.64 on Thursday, driven by a 50% surge in trading volume to 3.47 million shares, despite reporting a quarterly loss of GBX 0.09 per share and negative financial metrics. 该公司价值536万英镑,正在开发Nuvec,这是一个基于RNA疗法的专有基因传送平台,有可能口服、稳定和多疗法使用。 The company, valued at £5.36 million, is developing Nuvec®, a proprietary gene delivery platform for RNA-based therapies, with potential for oral delivery, stability, and multi-therapy use. 其主导方案N4 101是治疗炎症肠胃疾病的口服抗炎治疗,作为概念的证明。 Its lead program, N4 101, is an oral anti-inflammatory treatment for inflammatory bowel disease, serving as a proof-of-concept. N4 Pharma正在推进临床预科数据,以支持未来的临床试验和潜在的许可交易。 N4 Pharma is advancing preclinical data to support future clinical trials and potential licensing deals.